• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vector Partners Limited

    Alcami

    IDT Biologika

    Qosina

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Vector Partners Limited

    Alcami

    IDT Biologika

    Qosina

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: CMOs and CDMOs Have a Trade Association to Call Their Own

    The new Pharma & Biopharma Outsourcing Association aims to help advance the industry’s regulatory, legislative and business interests.

    Related CONTENT
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Mogene
    • Metrics Contract Services
    • Halo Pharma Forms Pediatric Center of Excellence
    • So You Think You Know All About Excipients?
    11.13.14
    A new non-profit trade association—The Pharma & Biopharma Outsourcing Association, or PBOA, has been formed to advocate industry causes.

    The association was conceived and launched by former Contract Pharma editor Gil Roth because, he said, “The CMO/CDMO industry has grown tremendously in the past 15 years, but the absence of a group like the PBOA has kept it from reaching its full potential.”

    So far fifteen CMOs/CDMOs have climbed aboard, representing large and small molecule manufacturers, from APIs to finished dosage forms, with members covering the gamut from single-site to globally networked companies.

    In addition to advocating and representing its industry before regulatory, governmental, and legislative bodies, PBOA hopes to educate pharma and biopharma companies, the general public and other stakeholders on the value that CMOs/CDMOs bring to the development and manufacture of therapeutics.

    Contract Pharma talked to Gil about the association’s beginnings and what the plans are moving forward. For more information about the PBOA, visit www.pharma-bio.org, or contact Gil at gil.roth@pharma-bio.org.

    –TW



    Contract Pharma: Tell me about the PBOA. What is it, how will it work and who can benefit from it?
    Gil Roth: The Pharma & Biopharma Outsourcing Association is a non-profit trade association that represents contract manufacturing organizations and contract development and manufacturing organizations (CMO/CDMOs). As we start out, we’re focused on companies that operate in or sell into the U.S. If you’re a CMO or CDMO that interacts with FDA, we want to be your go-to trade group.

    We’ll work to bring our members into the conversation with FDA, Congress, and other trade groups that affect the industry. We’ve partnered with a Washington, DC-area law firm that will provide both regulatory and legislative monitoring and help us reach the offices we need to reach, in order to get our message heard.

    CP: Since the launch how are things going so far? What kind of response/feedback have you had from the industry?
    GR: I’ve been very gratified by the response from industry. I began recruiting member companies in March of this year, and we quickly built a core of 15 members that were enthusiastic about giving this industry a voice. The founding members include Afton Scientific, Coldstream Laboatories, Cook Pharmica, Gallus Biopharmaceuticals, Halo Pharma, Hospira One 2 One, Jubilant HollisterStier, Metrics Contract Services, Patheon, Therapure Biomanufacturing, and WellSpring Pharma Services. We also added “Day One” general members in AAIPharma Services/Cambridge Major Labs, Coating Place, Confab Labs and DPT.

    Those founding members each nominated a member to our board of trustees, and the board has done a great job of getting the PBOA off the ground. As you can see from the list of companies, the PBOA is bigger than any one sector of the CMO/CDMO market, covering dosage form and drug substance, biologics and small molecules, sterile injectables and oral solid dosages, and development through commercial. Our trustees help guide the agenda for the PBOA, while also providing me with management expertise, recruitment heft, and a lot of other capabilities. The board members are willing to be active participants and have helped me reach out to more potential members.

    We’re also in the process of building a strong advisory committee, chaired by PharmSource president Jim Miller and including industry veterans from both the client and provider sides.

    CP: What were the key drivers behind the establishment of the association?
    GR: The idea for a trade association came about when I was reporting on an article for Contract Pharma early in 2013. It was on the topic of the Generic Drug User Fee Amendments (GDUFA), and a number of CMOs I spoke to felt that the allocation of facility fees was unfair. The more I researched and reported, the clearer it became that there was no one advocating for the CMOs’ interests during the GDUFA negotiating sessions, when those fees were being structured.

    I began asking around the industry whether a trade association would be a good idea. Even the companies that weren’t complaining about GDUFA—either because they’re not in the generics space or their companies also have their own generic lines—understood that it’s important that our industry has representation and that we need to have a coordinated message.

    So, the consensus was that a trade association would be a great idea, but no one was in a position to launch and run one.
    Shortly after that, a group of biologics-oriented CMOs approached me at BIO 2013 and wanted to get my thoughts about assembling a trade association for CMO/CDMOs. None of that group had been part of my informal poll, but they’d developed the same idea on their own.

    With their support, I organized a symposium with around 30 CMO/CDMOs, in September 2013, the night before Contract Pharma’s annual conference and exhibition, and received great response and feedback from the assembled group. It seemed like the time was right to build an association to represent this industry in Washington and beyond. It took a few months for me to realize that I wasn’t going to be able to get it rolling while I was still at Contract Pharma.

    CP: What opportunity does this represent for contract manufacturers? How will inclusion help benefit business?
    GR: The PBOA represents the first real opportunity for CMO/CDMOs to have their voices heard as an industry. In addition to our goals of outreach to regulatory and legislative bodies—that is, FDA and Congress—we’re also intent on working with the customer side of the industry. The PBOA can help disseminate best practices and get clients and providers to work together more effectively. More than that, we can get member companies talking to each other, through networking events, workshops and the like.

    The PBOA has three key areas:
    1. Advocacy/Representation with regulatory and government agencies. Our goal is to serve as the guidance organization for regulatory agencies globally when legislation and policy affect the industry. We will work to ensure the development of laws and policies that promote balanced oversight and the advancement of our industry.

    2. Education of members, customers, and general public. We’ll monitor legislation, regulation and media activity that impacts the CDMO industry and provide analyses to members to help them be prepared to address changes. We plan to offer excellent networking, information-sharing and educational resources designed to keep members informed of industry issues. We will educate customers and other stakeholders about the value CDMOs bring to the pharma and biopharma industries.

    3. Collaboration around common industry goals. Our members will help develop our agenda regarding issues that affect our industry and can simplify or promote the efficient growth of our businesses. Some initiatives include common third-party auditors program acceptance, Business Solutions partnerships to provide discounts on goods and services that our members use, and industry research to help get a better picture of the CMO/CDMO industry.

    CP: What are the obstacles to getting off the ground and what do you perceive will be the major challenges to making the association a success?
    GR: I think the biggest obstacle is that no one has ever done this before for our industry. It’s a cliché, but it really is both an obstacle and an opportunity.

    When I began recruiting companies to join the PBOA last spring, one person said to me, “When I joined the industry six years ago, the first thing I asked my company was, ‘What trade associations do we belong to?’ When they told me there aren’t any, I started to worry that I made the wrong career choice.’” That company joined on the spot.

    Still, the CMO/CDMO industry has a lot of players that are so concerned about the day-to-day operation that they don’t have time to step back and take in a broader, longer-term perspective. So it can be a challenge to get them to take that step back, and then to make the investment in time, money and resources that the PBOA requires.

    It’s amazing that we’ve come as far as we have without having any sort of collective body in place to advocate for the industry, but given the pressures that the entire healthcare ecosystem is experiencing, it’s not a state of affairs that can last much longer. I like to cite a quote that’s been attributed to a variety of Louisiana politicians, “If you’re not at the table, then you’re probably on the menu.”

    CP: Describe your interaction with FDA. Have they been receptive to the PBOA?
    GR: Our first meeting with FDA came about somewhat by accident, but we were well received. Along with two members of our Board, I attended a public hearing about several GDUFA guidances in September. We didn’t think the topics would be relevant to the CMO/CDMO side of things, but we wanted to get a feel for this sort of hearing, to see what the presentations were like and how the FDA panel conducted its questioning.

    Lo and behold, the second presentation was from a small generic drug company and was focused completely on GDUFA’s facility fees and how the “no-waiver” policy was unfair to smaller manufacturers. Both trustees nudged me to sign up for the open comments portion at the end of the morning session, where I would get five minutes at the podium in front of the FDA panel. I did, then began scribbling notes about GDUFA, facility fees, the bill that one of our members lobbied his Representative to introduce (H.R. 3631, the Small Manufacturer Protection Act), which would permit FDA to waive those fees for companies under a certain threshold, and more.

    When my turn came up, I took to the podium, adjusted my tie, and introduced the PBOA to the FDA on the public record. My presentation only took up a few minutes, and focused on the need for more interaction between FDA—not just the Office of Generic Drugs—and CMOs/CDMOs. The panel members’ questions were cordial and it really felt like they were welcoming us aboard. They seemed legitimately interested in understanding more about this business and how it differs from in-house pharma and biopharma operations.

    CP: What are the PBOA’s ultimate goals, both short- and long-term?
    GR: In the short term, we want to build bridges to connect the CMO/CDMO industry with FDA and Congress, educate both clients and providers about best outsourcing practices, and bring our industry into the 21st century.

    In the middle term, if we can succeed with our initiative in developing baseline auditing standards between manufacturers and clients, we can not only provide savings for both parties, we may be able to demonstrate to FDA and other regulatory bodies that CMO/CDMOs are committed to quality above and beyond cGMP. Along with our regulatory/legislative advocacy activities, that could go a long way toward changing the image of our industry.

    In the long term, if this model works, we could expand into other areas of outsourcing, as well as other geographic regions. But I spent enough years writing articles about the perils of “scope creep” to know that we need to stick with our initial mission. 
    Related Searches
    • cGMP
    • Biomanufacturing
    • Manufacturing
    • biopharma companies
    Suggested For You
    5 Reasons Paper Has No Place in Contract Manufacturing 5 Reasons Paper Has No Place in Contract Manufacturing
    Mogene Mogene
    Metrics Contract Services Metrics Contract Services
    Halo Pharma Forms Pediatric Center of Excellence Halo Pharma Forms Pediatric Center of Excellence
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Aseptic Manufacturing Trends Roundtable Aseptic Manufacturing Trends Roundtable
     Vantage Consulting is First Systems Integrator to Join PBOA Vantage Consulting is First Systems Integrator to Join PBOA
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing
    DCAT Week DCAT Week '17 Q&A: API Market Trends
    PBOA President Discusses the Future of the CMO Industry at INTERPHEX PBOA President Discusses the Future of the CMO Industry at INTERPHEX
    Whither Washington? Whither Washington?
    The Good, the Bad, and the Donald The Good, the Bad, and the Donald
    GDUFA II Update GDUFA II Update

    Related Content

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Formulation Development | Methods Development | Validation
      Metrics Contract Services

      Metrics Contract Services

      ...
      Dee D. Harper, Marketing and Communications Lead 12.04.19


    • Breaking News | cGMP Manufacture | Facilities | Industry News | Solid Dosage/Creams/Ointments
      Halo Pharma Forms Pediatric Center of Excellence

      Halo Pharma Forms Pediatric Center of Excellence

      Will be dedicated to the development, reformulation, and manufacturing of drug products in pediatric dosage forms
      05.10.17

    • Excipients
      So You Think You Know  All About Excipients?

      So You Think You Know All About Excipients?

      New scientific findings may change long-held perceptions about the nature of excipients
      Ben Locwin, Consultant 05.09.17

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      • Insmed Appoints Drayton Wise as Chief Commercial Officer
      • Clinigen Expands U.S. Site Capacity
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Blue Spark Technologies Raises $40 Million
      Pediatric Medical Device Competition Reveals Five Finalists
      Medical Device Packaging Market to Reach $34B by 2027
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      TikToker Abbie Herbert, Founder of Personal Care Brand Pavot, Launches Body Water, Razor Burn Treatment Pads With Beaubble Partnership
      E.l.f. Cosmetics Introduces ‘Big Mood Pride Mascara’ Ahead of Pride Month
      Ink World

      Latest Breaking News From Ink World

      PICO Chemical Celebrates 46 Years
      Epson Introduces Two New SurePress Digital Label Presses
      Flint Group Flexible Packaging Europe Implements Further Price Increase
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      InnovationLab Acquires Flexible Printed Battery Technology from Evonik
      Canatu Receives IATF 16949:2016 Certification
      Applied Materials Announces 2Q 2022 Results

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login